Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Psoriasis | 20 | 2024 | 945 | 5.330 |
Why?
|
Stevens-Johnson Syndrome | 13 | 2023 | 246 | 4.910 |
Why?
|
Skin Diseases | 12 | 2024 | 1095 | 3.050 |
Why?
|
Dermatology | 10 | 2024 | 918 | 1.820 |
Why?
|
Sarcoidosis | 5 | 2024 | 537 | 1.500 |
Why?
|
Skin Diseases, Vesiculobullous | 2 | 2022 | 85 | 1.470 |
Why?
|
Vaccines | 3 | 2024 | 835 | 1.450 |
Why?
|
Pemphigoid, Bullous | 3 | 2024 | 112 | 1.180 |
Why?
|
Vaccination | 7 | 2023 | 3368 | 0.900 |
Why?
|
Pemphigus | 1 | 2024 | 107 | 0.840 |
Why?
|
Drug Prescriptions | 4 | 2021 | 1669 | 0.810 |
Why?
|
Severity of Illness Index | 13 | 2024 | 15845 | 0.710 |
Why?
|
Eczema | 1 | 2023 | 246 | 0.700 |
Why?
|
Dermatologic Agents | 3 | 2020 | 313 | 0.680 |
Why?
|
Ultraviolet Therapy | 1 | 2019 | 84 | 0.640 |
Why?
|
Granuloma | 2 | 2017 | 327 | 0.610 |
Why?
|
Skin | 7 | 2023 | 4473 | 0.550 |
Why?
|
Papillomavirus Vaccines | 1 | 2022 | 496 | 0.530 |
Why?
|
Drug Administration Schedule | 1 | 2024 | 4849 | 0.530 |
Why?
|
Ultrasonography, Doppler, Color | 1 | 2017 | 232 | 0.530 |
Why?
|
Immunocompromised Host | 1 | 2021 | 858 | 0.520 |
Why?
|
Cyclosporine | 1 | 2018 | 776 | 0.490 |
Why?
|
Pharmacoepidemiology | 1 | 2018 | 351 | 0.460 |
Why?
|
Hidradenitis Suppurativa | 3 | 2023 | 177 | 0.450 |
Why?
|
Autoimmune Diseases | 2 | 2024 | 2243 | 0.450 |
Why?
|
Immunosuppressive Agents | 3 | 2021 | 4189 | 0.450 |
Why?
|
Biological Products | 3 | 2019 | 913 | 0.450 |
Why?
|
Drug Utilization | 1 | 2019 | 1188 | 0.430 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 1812 | 0.410 |
Why?
|
Mycosis Fungoides | 1 | 2013 | 170 | 0.380 |
Why?
|
Influenza Vaccines | 1 | 2018 | 767 | 0.370 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2013 | 212 | 0.360 |
Why?
|
Papillomavirus Infections | 1 | 2022 | 1615 | 0.360 |
Why?
|
Pemphigoid Gestationis | 1 | 2010 | 5 | 0.360 |
Why?
|
Pyoderma Gangrenosum | 2 | 2023 | 84 | 0.330 |
Why?
|
Epidermolysis Bullosa Acquisita | 1 | 2008 | 15 | 0.320 |
Why?
|
Adult | 30 | 2024 | 221083 | 0.320 |
Why?
|
Collagen Type VII | 1 | 2008 | 22 | 0.320 |
Why?
|
Humans | 68 | 2024 | 761098 | 0.310 |
Why?
|
Eosinophilia | 2 | 2023 | 557 | 0.310 |
Why?
|
Hospital Mortality | 2 | 2021 | 5296 | 0.310 |
Why?
|
Trophoblasts | 1 | 2010 | 223 | 0.310 |
Why?
|
Arthritis, Psoriatic | 3 | 2021 | 219 | 0.300 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3808 | 0.300 |
Why?
|
Middle Aged | 34 | 2024 | 220835 | 0.290 |
Why?
|
Mohs Surgery | 2 | 2021 | 222 | 0.290 |
Why?
|
Influenza, Human | 1 | 2018 | 1521 | 0.280 |
Why?
|
Models, Theoretical | 1 | 2019 | 3568 | 0.280 |
Why?
|
Hepatitis C | 1 | 2017 | 1579 | 0.280 |
Why?
|
Chronic Disease | 5 | 2023 | 9317 | 0.280 |
Why?
|
Female | 39 | 2024 | 392458 | 0.270 |
Why?
|
Paraproteinemias | 2 | 2020 | 250 | 0.270 |
Why?
|
Autoantibodies | 3 | 2010 | 2117 | 0.260 |
Why?
|
United States | 14 | 2023 | 72337 | 0.260 |
Why?
|
Male | 36 | 2024 | 360675 | 0.250 |
Why?
|
Leukopenia | 2 | 2022 | 213 | 0.230 |
Why?
|
Electronic Health Records | 6 | 2024 | 4813 | 0.220 |
Why?
|
Biomedical Research | 1 | 2018 | 3429 | 0.200 |
Why?
|
Acute Generalized Exanthematous Pustulosis | 1 | 2022 | 14 | 0.200 |
Why?
|
Liver | 1 | 2017 | 7513 | 0.190 |
Why?
|
Quality of Life | 2 | 2021 | 13362 | 0.190 |
Why?
|
Skin Neoplasms | 3 | 2019 | 5809 | 0.180 |
Why?
|
Placenta | 1 | 2010 | 1709 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2013 | 4372 | 0.180 |
Why?
|
Necrobiotic Xanthogranuloma | 1 | 2020 | 10 | 0.180 |
Why?
|
Risk Assessment | 3 | 2019 | 24013 | 0.180 |
Why?
|
Transdermal Patch | 1 | 2020 | 51 | 0.170 |
Why?
|
Non-Fibrillar Collagens | 2 | 2010 | 25 | 0.170 |
Why?
|
Perforin | 1 | 2020 | 166 | 0.170 |
Why?
|
Retrospective Studies | 17 | 2023 | 80673 | 0.170 |
Why?
|
Fas Ligand Protein | 1 | 2020 | 216 | 0.170 |
Why?
|
Necrobiosis Lipoidica | 1 | 2019 | 14 | 0.160 |
Why?
|
Aged | 18 | 2023 | 169266 | 0.160 |
Why?
|
Sulfamethoxazole | 1 | 2018 | 51 | 0.160 |
Why?
|
Trimethoprim | 1 | 2018 | 78 | 0.150 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2020 | 897 | 0.150 |
Why?
|
Immune System Diseases | 1 | 2020 | 254 | 0.150 |
Why?
|
Sweet Syndrome | 1 | 2017 | 58 | 0.140 |
Why?
|
Phototherapy | 1 | 2020 | 368 | 0.140 |
Why?
|
Thrombocytopenia | 2 | 2022 | 1182 | 0.140 |
Why?
|
Population Surveillance | 2 | 2017 | 2599 | 0.140 |
Why?
|
Whole Body Imaging | 1 | 2019 | 284 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 2 | 2021 | 3197 | 0.140 |
Why?
|
Cellulitis | 1 | 2018 | 208 | 0.130 |
Why?
|
Keratinocytes | 1 | 2020 | 790 | 0.130 |
Why?
|
Adrenal Cortex Hormones | 3 | 2023 | 1878 | 0.130 |
Why?
|
Nevus, Sebaceous of Jadassohn | 1 | 2015 | 3 | 0.130 |
Why?
|
Autoantigens | 2 | 2010 | 887 | 0.120 |
Why?
|
Prognosis | 4 | 2023 | 29672 | 0.120 |
Why?
|
Withholding Treatment | 1 | 2019 | 616 | 0.120 |
Why?
|
Cohort Studies | 6 | 2020 | 41486 | 0.120 |
Why?
|
Physician's Role | 1 | 2021 | 916 | 0.120 |
Why?
|
Acute Disease | 2 | 2023 | 7240 | 0.120 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2015 | 82 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1790 | 0.120 |
Why?
|
Clostridium Infections | 1 | 2021 | 557 | 0.120 |
Why?
|
Arthritis, Rheumatoid | 3 | 2018 | 3754 | 0.110 |
Why?
|
Anticonvulsants | 2 | 2023 | 1911 | 0.110 |
Why?
|
Comorbidity | 4 | 2022 | 10514 | 0.110 |
Why?
|
Incidental Findings | 1 | 2019 | 698 | 0.110 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2018 | 668 | 0.110 |
Why?
|
Blood Vessels | 1 | 2019 | 1111 | 0.110 |
Why?
|
Survival Rate | 2 | 2018 | 12727 | 0.110 |
Why?
|
Sweat Gland Neoplasms | 1 | 2015 | 116 | 0.110 |
Why?
|
Prevalence | 5 | 2022 | 15717 | 0.110 |
Why?
|
Young Adult | 7 | 2023 | 59199 | 0.110 |
Why?
|
Immunoglobulin E | 2 | 2010 | 1505 | 0.110 |
Why?
|
Anti-Infective Agents | 1 | 2020 | 983 | 0.100 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 26068 | 0.100 |
Why?
|
Th17 Cells | 1 | 2019 | 794 | 0.100 |
Why?
|
Risk Factors | 7 | 2021 | 74219 | 0.100 |
Why?
|
Arthritis | 1 | 2018 | 681 | 0.100 |
Why?
|
Morbidity | 1 | 2018 | 1750 | 0.100 |
Why?
|
Scalp | 1 | 2015 | 389 | 0.100 |
Why?
|
Administration, Oral | 1 | 2020 | 4014 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3803 | 0.100 |
Why?
|
Incidence | 6 | 2021 | 21357 | 0.090 |
Why?
|
Patient Education as Topic | 1 | 2021 | 2316 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2015 | 592 | 0.090 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2194 | 0.090 |
Why?
|
Colitis, Ulcerative | 1 | 2023 | 1921 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2020 | 1589 | 0.090 |
Why?
|
Treatment Outcome | 5 | 2024 | 64670 | 0.090 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2270 | 0.090 |
Why?
|
Decision Making | 1 | 2024 | 3925 | 0.090 |
Why?
|
Research Design | 3 | 2024 | 6178 | 0.090 |
Why?
|
Health Personnel | 1 | 2023 | 3335 | 0.090 |
Why?
|
Neoplasms | 4 | 2020 | 22125 | 0.080 |
Why?
|
Survivors | 1 | 2020 | 2369 | 0.080 |
Why?
|
Medicaid | 1 | 2022 | 2814 | 0.080 |
Why?
|
Liver Diseases | 1 | 2017 | 1300 | 0.080 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2008 | 66 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2020 | 4340 | 0.080 |
Why?
|
Microscopy, Immunoelectron | 1 | 2008 | 317 | 0.080 |
Why?
|
Consensus | 3 | 2023 | 3133 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2023 | 4013 | 0.080 |
Why?
|
Aged, 80 and over | 5 | 2019 | 58946 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2508 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3535 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4574 | 0.070 |
Why?
|
Inpatients | 1 | 2018 | 2545 | 0.070 |
Why?
|
Feasibility Studies | 1 | 2017 | 5249 | 0.070 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15308 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10755 | 0.060 |
Why?
|
Inflammation | 3 | 2022 | 10758 | 0.060 |
Why?
|
Antibody Formation | 1 | 2010 | 1391 | 0.060 |
Why?
|
Biopsy | 1 | 2017 | 6781 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2018 | 1868 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2018 | 3603 | 0.060 |
Why?
|
Communication | 1 | 2019 | 3852 | 0.060 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2017 | 3367 | 0.060 |
Why?
|
Apoptosis | 1 | 2020 | 9478 | 0.060 |
Why?
|
Pilot Projects | 1 | 2017 | 8639 | 0.060 |
Why?
|
Imaging, Three-Dimensional | 1 | 2017 | 4060 | 0.060 |
Why?
|
Epitopes | 1 | 2010 | 2503 | 0.060 |
Why?
|
Sex Factors | 1 | 2017 | 10552 | 0.050 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2018 | 2423 | 0.050 |
Why?
|
Adolescent | 6 | 2022 | 88271 | 0.050 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2022 | 2025 | 0.050 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2017 | 3609 | 0.050 |
Why?
|
Time Factors | 3 | 2019 | 39953 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10712 | 0.050 |
Why?
|
Clindamycin | 1 | 2021 | 139 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2017 | 20120 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5841 | 0.040 |
Why?
|
Vaccines, Attenuated | 1 | 2021 | 315 | 0.040 |
Why?
|
Opiate Alkaloids | 1 | 2019 | 28 | 0.040 |
Why?
|
Biological Transport | 1 | 2024 | 2082 | 0.040 |
Why?
|
Delphi Technique | 1 | 2023 | 849 | 0.040 |
Why?
|
Mental Disorders | 1 | 2019 | 6818 | 0.040 |
Why?
|
Iowa | 1 | 2019 | 104 | 0.040 |
Why?
|
Prospective Studies | 3 | 2020 | 54419 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17889 | 0.040 |
Why?
|
Potassium Iodide | 1 | 2017 | 14 | 0.040 |
Why?
|
North America | 1 | 2021 | 1281 | 0.040 |
Why?
|
Interleukin-23 | 1 | 2019 | 201 | 0.040 |
Why?
|
Dapsone | 1 | 2017 | 56 | 0.040 |
Why?
|
Filgrastim | 1 | 2017 | 132 | 0.040 |
Why?
|
Folic Acid Antagonists | 1 | 2017 | 75 | 0.040 |
Why?
|
Hematologic Agents | 1 | 2017 | 40 | 0.040 |
Why?
|
Body Surface Area | 1 | 2017 | 197 | 0.040 |
Why?
|
Tubulin Modulators | 1 | 2017 | 107 | 0.040 |
Why?
|
Temperature | 1 | 2023 | 2219 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15513 | 0.030 |
Why?
|
Interleukin-12 | 1 | 2019 | 578 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 12937 | 0.030 |
Why?
|
Spondylitis, Ankylosing | 1 | 2018 | 155 | 0.030 |
Why?
|
Databases, Factual | 2 | 2024 | 7969 | 0.030 |
Why?
|
Polycythemia Vera | 1 | 2018 | 161 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2019 | 15634 | 0.030 |
Why?
|
Colchicine | 1 | 2017 | 258 | 0.030 |
Why?
|
Fluorine Radioisotopes | 1 | 2019 | 420 | 0.030 |
Why?
|
Fever | 1 | 2023 | 1618 | 0.030 |
Why?
|
Thyroid Diseases | 1 | 2019 | 386 | 0.030 |
Why?
|
Asymptomatic Diseases | 1 | 2019 | 588 | 0.030 |
Why?
|
Botswana | 1 | 2018 | 1049 | 0.030 |
Why?
|
Cystadenoma | 1 | 2015 | 79 | 0.030 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2015 | 27 | 0.030 |
Why?
|
Placebos | 1 | 2019 | 1666 | 0.030 |
Why?
|
Disease Progression | 2 | 2023 | 13506 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2010 | 18926 | 0.030 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2017 | 495 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1818 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2278 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 12145 | 0.030 |
Why?
|
Arthralgia | 1 | 2017 | 461 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2022 | 1747 | 0.030 |
Why?
|
Age Distribution | 1 | 2019 | 2873 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2081 | 0.030 |
Why?
|
Anti-Bacterial Agents | 2 | 2022 | 7405 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1596 | 0.030 |
Why?
|
Research | 1 | 2021 | 1975 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2022 | 2160 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2018 | 934 | 0.030 |
Why?
|
Dyslipidemias | 1 | 2019 | 870 | 0.020 |
Why?
|
Perioperative Care | 1 | 2019 | 1037 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1885 | 0.020 |
Why?
|
Radiopharmaceuticals | 1 | 2019 | 2682 | 0.020 |
Why?
|
Child | 3 | 2021 | 80134 | 0.020 |
Why?
|
Pregnancy | 1 | 2010 | 29872 | 0.020 |
Why?
|
Anemia | 1 | 2017 | 1504 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2757 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39121 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2017 | 22157 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10083 | 0.020 |
Why?
|
Critical Care | 1 | 2018 | 2690 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12341 | 0.020 |
Why?
|
Cytokines | 1 | 2019 | 7386 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2023 | 7873 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2017 | 5781 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 8000 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5145 | 0.010 |
Why?
|
Smoking | 1 | 2019 | 9055 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2009 | 2637 | 0.010 |
Why?
|
Blotting, Western | 1 | 2009 | 5033 | 0.010 |
Why?
|
Age Factors | 1 | 2018 | 18385 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12975 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 26187 | 0.010 |
Why?
|
Hypertension | 1 | 2019 | 8537 | 0.010 |
Why?
|
Infant | 1 | 2019 | 36164 | 0.010 |
Why?
|
Child, Preschool | 1 | 2019 | 42217 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 14676 | 0.010 |
Why?
|
Mutation | 1 | 2017 | 30006 | 0.010 |
Why?
|
Concepts
(243)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(20)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_